Slow Bull
The market, slowly. SATURDAY, 26 SEPTEMBER 2026

Nautilus Biotechnology, Inc.

NAUT Nasdaq SEC CIK 1808805
Follow Nautilus Biotechnology Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Revenue, last quarter $190K
Net income −$14.5M +3.8% vs same quarter last year
EPS, diluted −$0.11 +8.3% vs same quarter last year
Operating cash flow −$13.7M −2.8% vs same quarter last year
Revenue by quarter
$0
$190K
Q2 25 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$80M−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$59M
FY24−$70.8M
FY23−$63.7M
FY22−$57.9M
FY21−$50.3M
FY20−$15.6M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$52M
FY24−$61.3M
FY23−$54.2M
FY22−$48.1M
FY21−$41.5M
FY20−$14.9M
FY19-

News

No stories filed under Nautilus Biotechnology yet - coverage appears here as the news feed clusters it.